Previous 10 | Next 10 |
SEATTLE, July 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online launch of company CEO Steven Quay ...
SEATTLE, July 17, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported that patients and their doctors can now visit the ...
Immunic (NASDAQ: IMUX ) +17% . More news on: Immunic, Inc., Foresight Autonomous Holdings Ltd., Jaguar Health, Inc., Stocks on the move, Read more ...
SEATTLE, July 11, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it is developing a new proprietary modified-...
Gainers: Cemtrex (NASDAQ: CETX ) +120% . The Howard Hughes (NYSE: HHC ) +38% . J.Jill (NYSE: JILL ) +21% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +21% . Zogenix (NASDAQ: ZGNX ) +21% . Herman Miller (NASDAQ: MLHR ) +18% . Atossa Genetics (NASDAQ: ATOS ) +16% . Dova...
Nano cap Atossa Genetics (NASDAQ: ATOS ) is up 29% premarket on robust volume in reaction to positive results from a 90-subject Phase 2 clinical trial assessing daily 20 mg doses of topical Z Endoxifen on mammographic breast density (MBD). More news on: Atossa Genetics Inc., ...
Dova Pharmaceuticals (NASDAQ: DOVA ) +32% as FDA OKs Dova's Doptelet for low blood platelets in ITP patients. More news on: Dova Pharmaceuticals, Inc., Atossa Genetics Inc., Zogenix, Inc., Stocks on the move, Read more ...
SEATTLE, June 27, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary analysis from its recently com...
SEATTLE, May 30, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle Guse, CFO, will be a featured pres...
SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2019 / Vista Partners ("Vista") has published May 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Trade War Jitters?". Vista's monthly newsletter contains macroeconomic views & investment considerations that center around Vista...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...